Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCBP2 siRNA nanoparticles
- Development stage
- Preclinical
- Lead developer
- University of Missouri-Kansas City
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PCBP2 siRNA nanoparticles are an experimental RNA interference (RNAi) therapeutic consisting of small interfering RNA (siRNA) encapsulated within a nanoparticle delivery system. The siRNA is designed to target and silence the poly(rC)-binding protein 2 (PCBP2) gene, also known as αCP2. PCBP2 is an RNA-binding protein that plays a critical role in stabilizing type I collagen mRNA in myofibroblasts and pancreatic stellate cells. By silencing PCBP2, the therapy destabilizes collagen mRNA, leading to a reduction in collagen deposition and the normalization of the dense, fibrotic tumor stroma characteristic of pancreatic ductal adenocarcinoma (PDAC). This stromal normalization is intended to alleviate physical barriers to drug delivery and immune cell infiltration, thereby enhancing the efficacy of other treatments such as anti-PD-L1 immunotherapy. The program is currently in preclinical development, primarily associated with research from the University of Missouri-Kansas City.
- Other names
- PCBP2 siRNAPCBP-2 siRNAPCBP 2 siRNAαCP2 siRNA nanoparticles
02
Targets
IGF2R (Cation-independent mannose-6-phosphate receptor)Poly(rC)-binding protein 2 mRNA
Beyond the preview
Go deeper on PCBP2 siRNA nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCBP2 siRNA nanoparticles.